{"DataElement":{"publicId":"6820502","version":"1","preferredName":"Mixed Phenotype Acute Leukemia Therapeutic Procedure Administered Type","preferredDefinition":"The response to a question asking about the type of therapy administered to MPAL patients.","longName":"MPAL_TX_ADM_TP","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"6820498","version":"1","preferredName":"Mixed Phenotype Acute Leukemia Therapeutic Procedure Administered","preferredDefinition":"An acute leukemia of ambiguous lineage.  It is characterized by the presence of either separate populations of blasts of more than one lineage, or one population of blasts co-expressing markers of more than one lineage._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._The act of having given something (e.g., a medication or test).","longName":"6820496v1.0:2233610v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"6820496","version":"1","preferredName":"Mixed Phenotype Acute Leukemia Therapeutic Procedure","preferredDefinition":"An acute leukemia of ambiguous lineage.  It is characterized by the presence of either separate populations of blasts of more than one lineage, or one population of blasts co-expressing markers of more than one lineage.:An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","longName":"C82179:C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Phenotype Acute Leukemia","conceptCode":"C82179","definition":"An acute leukemia of ambiguous lineage.  It is characterized by the presence of either separate populations of blasts of more than one lineage, or one population of blasts co-expressing markers of more than one lineage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E46B168-4F21-69A9-E053-F662850A9344","latestVersionIndicator":"Yes","beginDate":"2019-07-22","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-22","modifiedBy":"ONEDATA","dateModified":"2019-07-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E46B168-4F2F-69A9-E053-F662850A9344","latestVersionIndicator":"Yes","beginDate":"2019-07-22","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-22","modifiedBy":"SETRAKIN","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6820483","version":"1","preferredName":"Therapeutic Procedure Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"6820483v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"AML therapy","valueDescription":"Acute Myeloid Leukemia Therapeutic Procedure","ValueMeaning":{"publicId":"6820485","version":"1","preferredName":"Acute Myeloid Leukemia Therapeutic Procedure","longName":"6820485","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E49534F-E140-0932-E053-F662850A840A","latestVersionIndicator":"Yes","beginDate":"2019-07-22","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-22","modifiedBy":"ONEDATA","dateModified":"2019-07-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E49534F-E15B-0932-E053-F662850A840A","beginDate":"2019-07-22","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-22","modifiedBy":"ONEDATA","dateModified":"2019-07-22","deletedIndicator":"No"},{"value":"Recommended Block 2 AML therapy","valueDescription":"Acute Myeloid Leukemia Recommendation Therapeutic Procedure","ValueMeaning":{"publicId":"6820486","version":"1","preferredName":"Acute Myeloid Leukemia Recommendation Therapeutic Procedure","longName":"6820486","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).: Advice telling someone what the best thing to do is.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Recommendation","conceptCode":"C25197","definition":"Advice telling someone what the best thing to do is.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E49534F-E169-0932-E053-F662850A840A","latestVersionIndicator":"Yes","beginDate":"2019-07-22","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-22","modifiedBy":"ONEDATA","dateModified":"2019-07-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E49534F-E184-0932-E053-F662850A840A","beginDate":"2019-07-22","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-22","modifiedBy":"ONEDATA","dateModified":"2019-07-22","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"6424136","version":"1","preferredName":"Other","longName":"6424136","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"753441A1-068C-5A23-E053-F662850A6B7A","latestVersionIndicator":"Yes","beginDate":"2018-09-06","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-02-02","changeDescription":null,"administrativeNotes":"2023.2.2 Alt VM added per ticket request CADSR0002006. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E49534F-E18E-0932-E053-F662850A840A","beginDate":"2019-07-22","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-22","modifiedBy":"ONEDATA","dateModified":"2019-07-22","deletedIndicator":"No"},{"value":"Other AML therapy","valueDescription":"Acute Myeloid Leukemia Other Therapeutic Procedure","ValueMeaning":{"publicId":"6820488","version":"1","preferredName":"Acute Myeloid Leukemia Other Therapeutic Procedure","longName":"6820488","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).: Different than the one(s) previously specified or mentioned.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E49534F-E1C0-0932-E053-F662850A840A","latestVersionIndicator":"Yes","beginDate":"2019-07-22","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-22","modifiedBy":"ONEDATA","dateModified":"2019-07-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E49534F-E1DB-0932-E053-F662850A840A","beginDate":"2019-07-22","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-22","modifiedBy":"ONEDATA","dateModified":"2019-07-22","deletedIndicator":"No"},{"value":"Recommended Block 1 AML therapy","valueDescription":"Acute Myeloid Leukemia Recommendation Therapeutic Procedure","ValueMeaning":{"publicId":"6820489","version":"1","preferredName":"Acute Myeloid Leukemia Recommendation Therapeutic Procedure","longName":"6820489","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).: Advice telling someone what the best thing to do is.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Recommendation","conceptCode":"C25197","definition":"Advice telling someone what the best thing to do is.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E49534F-E1E5-0932-E053-F662850A840A","latestVersionIndicator":"Yes","beginDate":"2019-07-22","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-22","modifiedBy":"ONEDATA","dateModified":"2019-07-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E49534F-E1FF-0932-E053-F662850A840A","beginDate":"2019-07-22","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-22","modifiedBy":"ONEDATA","dateModified":"2019-07-22","deletedIndicator":"No"},{"value":"ALL therapy","valueDescription":"Acute Lymphoblastic Leukemia Therapeutic Procedure","ValueMeaning":{"publicId":"6820487","version":"1","preferredName":"Acute Lymphoblastic Leukemia Therapeutic Procedure","longName":"6820487","preferredDefinition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E49534F-E198-0932-E053-F662850A840A","latestVersionIndicator":"Yes","beginDate":"2019-07-22","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-22","modifiedBy":"ONEDATA","dateModified":"2019-07-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E84E4CD-5B22-31BA-E053-F662850AEAA3","beginDate":"2019-07-25","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E49534F-E100-0932-E053-F662850A840A","latestVersionIndicator":"Yes","beginDate":"2019-07-22","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-22","modifiedBy":"TAYLORT","dateModified":"2020-10-19","changeDescription":"10.19.2020 TL moved from APPRVD FOR TRIAL USE to RELEASED in preparation of MDR.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What type of therapy was admi","type":"Preferred Question Text","description":"What type of therapy was administered?","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Therapy administered for Block 1?","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E461EEC-2C9D-6693-E053-F662850A6B23","latestVersionIndicator":"Yes","beginDate":"2019-07-22","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-22","modifiedBy":"SETRAKIN","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}